Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know
01:00pm, Thursday, 07'th Nov 2024
Dare Bioscience (DARE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
08:00am, Thursday, 07'th Nov 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:3
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health
12:30pm, Wednesday, 23'rd Oct 2024
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management.
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
08:05am, Monday, 21'st Oct 2024
Provides Daré access to capital at Daré's discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-cate
Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript
08:40pm, Monday, 12'th Aug 2024
Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2024 Earnings Call Transcript August 12, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conferenc
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
06:15pm, Monday, 12'th Aug 2024
Dare Bioscience, Inc. (DARE) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of a loss of $0.57 per share. This compares to loss of $1.20 per share a year ago
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
04:01pm, Monday, 12'th Aug 2024
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 co
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
08:00am, Friday, 19'th Jul 2024
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
06:54am, Monday, 01'st Jul 2024
Ken Gayron to Step Down as a Member of the Company's Board Encinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announce
Daré Bioscience Announces Reverse Stock Split
08:00am, Thursday, 27'th Jun 2024
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and
Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript
06:30pm, Tuesday, 14'th May 2024
Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
08:00am, Tuesday, 14'th May 2024
Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the U
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
08:00am, Thursday, 02'nd May 2024
Daré joins a nationwide network working to accelerate transformative health solutions Daré joins a nationwide network working to accelerate transformative health solutions
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Dar
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
08:00am, Tuesday, 23'rd Apr 2024
Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases
